Anna Bratulic is a journalist with a focus on the pharmaceutical and biotech industries. She covers a wide range of topics, including drug development, clinical trials, regulatory updates, and business news. Anna has a keen interest in providing accurate and up-to-date information to readers in the healthcare and life sciences sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Anna's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly drug development, clinical trials, and FDA approvals. Her articles heavily feature press releases and cited data.
Given Anna’s focus on private sector announcements and reliance on data, she is likely to be responsive to pitches offering insights from professionals within the pharmaceutical industry who can provide in-depth analysis of new drugs or treatments. Pitches should highlight concrete data or exclusive details related to drug development processes, clinical trial results, or regulatory approvals.
While no specific geographic focus is mentioned for Anna's reporting, her topics cover international pharmaceutical developments rather than a localized perspective.
This information evolves through artificial intelligence and human feedback. Improve this profile .
AI drug discovery firm BenevolentAI announced a new restructuring initiative Tuesday that will see it reduce its headcount by about 30% and close
AI drug discovery firm BenevolentAI announced a new restructuring initiative Tuesday that will reduce its headcount by about 30% and close its US
Biogen said Wednesday that sales of the Alzheimer's disease treatment Leqembi (lecanemab) reached $19 million in the first quarter, nearly triple
Scoring a $132.5-million windfall, San Diego-based Endeavor BioMedicines has pulled off an oversubscribed series C round to support its frontrunner
The FDA on Wednesday approved UTILITY therapeutics' oral antibiotic Pivya (pivmecillinam) as a new treatment option for adult females with uncomplicated urinary tract infections (UTIs) caused by specific bacterial strains.
Sanofi and Regeneron Pharmaceuticals' dual IL-3 and IL-14 blocker Dupixent (dupilumab) is firmly entrenched as an initial-line treatment option for
The cancer immunotherapy saw sales surge 20% year-over-year to $6.9 billion in the first quarter, topping analyst estimates of $6.7 billion. Keytruda is the "star" of Merck's report, commented Edward Jones analyst John Boylan, adding "we expect that to continue due to growing acceptance of the drug and good clinical data."
GSK fired a new salvo in the high-stakes battle over mRNA vaccine technology patents, filing a lawsuit in US federal court that seeks to claim
AbbVie's first-quarter results presentation Friday revealed that newer anti-inflammatory treatments like Rinvoq and Skyrizi helped mitigate a
Perrigo is offloading its HRA Pharma Rare Diseases business to Barcelona-based pharmaceutical company Esteve Healthcare for a total of up to €275 million ($294 million). The transaction, which includes €190 million in cash upfront plus up to €85 million in potential earnouts if certain sales milestones are reached, is expected to close in the third quarter.
(833) 317-6278 
